NIPH Clinical Trials Search

Efficacy and safety of Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with hematological malignancies after highly emetogenic chemotherapy

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	hematological malignancies
Date of first enrollment	2011/06/01
Target sample size	100
Countries of recruitment	Japan
Study type	Interventional
Intervention(s)	Aprepitant on days 1 to 3 Granisetron on day 1 Dexamethasone on days 1 to 4 Granisetron on day 1 Dexamethasone on days 1 to 4

Outcome(s)

Primary Outcome	The proportion of patients with no emesis and no nausea in overall phase (0-120 hours after chemotherapy)
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Male and Female
Include criteria
Exclude criteria	1.Hypersensitivity for Aprepitant. 2.Patient is receiving treatment with pimozide.